Work

Targeting mitochondrial dysfunction across the lifespan: Role of bezafibrate in neurodevelopment and neurodegeneration

Year: 2026
Type: article
Abstract: Neurodevelopmental and neurodegenerative disorders have traditionally been viewed as distinct clinical entities, separated by age of onset and trajectory. However, emerging evidence suggests they represent different temporal phases of a continuous neurological spectrum. A central, shared mechanistic hub in this continuum is mitochondrial dysfunction, which impairs the formation and maintenance of neuronal and glial networks, delaying early maturation and heightening vulnerability to later-life decline. This perspective highlights the critical role of mitochondrial health, particularly within astrocytes, in maintaining synaptic homeostasis and network stability. Consequently, targeting mitochondrial pathways offers a promising cross-cutting therapeutic strategy. Specifically, bezafibrate, a pan-PPAR agonist commonly used for dyslipidemia, has demonstrated significant efficacy in restoring mitochondrial biogenesis and resilience via the PGC-1α pathway. Across various in vitro and in vivo models—including tauopathy-associated cortical and retinal organoids, as well as 22q11.2 deletion syndrome models—bezafibrate successfully rescues early neurodevelopmental delays (improving neuronal, synaptic, and glial maturation) and mitigates late-stage neurodegenerative phenotypes (reducing neurodegeneration, neuroinflammation, and protein aggregation). By bridging physiological and pharmacological pathways governing mitochondrial health, bezafibrate represents a robust therapeutic candidate for preserving brain function from early development through aging.
Language: English
Open Access status: gold
Estimated APC paid: $1,500
OpenAlex ID: W7127049371
FWCI: 1.266
Cites: 10
Cited by: 1
Related to: 10